All lobbying filings

STRATEGIC MARKETING INNOVATIONS

STRATEGIC MARKETING INNOVATIONS filed a Q4 report for TONIX PHARMACEUTICALS on January 21, 2026, reporting $10,000 in lobbying income.

Lobbying for TONIX PHARMACEUTICALS · Clinical-stage biopharmaceutical company

All filings by STRATEGIC MARKETING INNOVATIONS · Everything TONIX PHARMACEUTICALS has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 21, 2026

Income

$10,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Defense

Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.

Health Issues

Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.